title: Do rectal cancer patients with PIK3CA mutations benefit from preoperative radiotherapy with regard to local recurrences?
authors.forename: Youji
authors.initials: Y
authors.lastname: He
authors.forename: Laura J
authors.initials: LJ
authors.lastname: Van't Veer
authors.forename: Marta
authors.initials: M
authors.lastname: Lopez-Yurda
authors.forename: Cornelis J H
authors.initials: CJ
authors.lastname: van de Velde
authors.forename: Corrie A M
authors.initials: CA
authors.lastname: Marijnen
mesh_terms: D014408:Biomarkers, Tumor / Q000235:genetics; D002277:Carcinoma / Q000175:diagnosis / Q000235:genetics* / Q000532:radiotherapy* / Q000601:surgery; D058534:Class I Phosphatidylinositol 3-Kinases; D006801:Humans; D009154:Mutation / Q000502:physiology; D009364:Neoplasm Recurrence, Local / Q000175:diagnosis* / Q000235:genetics; D019869:Phosphatidylinositol 3-Kinases / Q000235:genetics*; D011237:Predictive Value of Tests; D057234:Preoperative Period; D011379:Prognosis; D018714:Radiotherapy, Adjuvant; D016032:Randomized Controlled Trials as Topic; D012004:Rectal Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000532:radiotherapy* / Q000601:surgery; D018570:Risk Assessment; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; D058534:Class I Phosphatidylinositol 3-Kinases; D019869:Phosphatidylinositol 3-Kinases; C484760:PIK3CA protein, human